Message #10 From:
Stock News Bot Date: October 24, 2006 05:30:00 AM
IOPM News IntraOp Delivers Mobetron to Nagoya University Hospital
SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (OTCBB: IOPM), a provider of
innovative technology solutions for the treatment and eradication of
cancer, today announced that it has delivered a Mobetron®
system to Nagoya University Hospital, in Nagoya, Japan. This is the 18th
Mobetron system delivered worldwide, and the second such system
delivered to Japan. The Mobetron is a proprietary, mobile electron-beam
instrument designed for Intraoperative Electron Radiation Therapy
(IOERT), the direct application of radiation to a tumor while a patient
is undergoing cancer surgery. Nagoya University Hospital is one of 80
hospitals in Japan with active IORT programs. However, almost all of
these centers transport the patient, in the midst of surgery, from the
operating room (OR) to the radiation department to receive the IORT
treatment. Although Japan is considered the birthplace of modern IORT,
the Nagoya Mobetron unit will be one of the first IOERT systems in the
country actually located in the OR.
“Together with our partner in Japan, Chiyoda
Technol Corporation, we have been working to introduce the Mobetron’s
modern IOERT technology to Japan,” said Dr.
Donald A. Goer, President and Chief Executive Officer of IntraOp. “With
the installation of the University of Nagoya, and the planned
installation of Gunma Prefecture Hospital early next year, these efforts
are beginning to bear fruit. Japan has a rich history of IOERT
innovation and adoption. If the Mobetron enables IOERT treatments to be
delivered with greater convenience and less cost and disruption, other
hospitals in Japan are likely to follow the example of Nagoya and Gunma.
Japan could become one of the major markets for our products.”
The hospital intends to focus initially on the use of IOERT for
pancreatic cancer. In Japan, IOERT is a standard component of the
treatment for this disease at many hospitals because the addition of
IOERT is significantly more effective in treating this disease than
using conventional treatments alone. Published studies from Japanese
hospitals that use IOERT to treat this disease show that there is
increased tumor control and better survival when used with intent to
cure in patients with resectable tumors, and, when used palliatively to
treat unresectable tumors, patients experience a higher quality of life
with more hospital free survival days. Another site that the University
will use the Mobetron for is early stage breast cancer. Breast cancer is
becoming an increasingly more common cancer in Japan, and the University
of Nagoya will be one of the first Japanese hospitals to offer the
benefits of IOERT to this patient population.
Nagoya, Japan’s fourth largest city and the
capital of Aichi prefecture, is located southwest of Tokyo. The Mobetron
at Nagoya University, one of the major cancer treatment centers in the
prefecture, is scheduled to begin clinical treatment before the end of
the year.
Abut IntraOp
IntraOp Medical Corporation provides innovative technology solutions for
the treatment and eradication of cancer. Founded in 1993, IntraOp is
committed to providing the tools doctors need to administer
intraoperative radiation therapy safely and effectively –
for all cancer patients. The company’s
flagship product, Mobetron, is the first fully portable, self-shielding
intraoperative electron radiation therapy device designed for use in any
operating room. Key Mobetron benefits include: increased survival rates,
better local tumor control, shorter treatment cycles, and fewer side
effects. Leading hospitals, from university research centers to
specialized cancer clinics in North America, Europe and Asia, use
Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
Forward-Looking Statements
This press release may contain "forward-looking statements" within
the meaning of Section 27A of the 1933 Securities Act and Section 21E of
the 1934 Securities Exchange Act. Actual results could differ
materially, as the result of such factors as competition in the markets
for the company's products and services and the ability of the Company
to execute its plans. By making these forward-looking statements, the
Company can give no assurances that transactions described in this press
release will be successfully completed, and undertakes no obligation to
update these statements for revisions or changes after the date of this
press release.
